Linker Information
General Information of This Linker
| Linker ID |
LIN0FPLKE
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Ab-MC-MMAF-VC-PAB-MK4827 Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C67H103N11O14
|
|||||
| Isosmiles |
CC([C@H](NC([C@@H](NC([C@@H]([C@@H](OC)[C@@H]1CCCN1C(C[C@@H](OC)[C@@H](N(C)C([C@@H](NC([C@H](C(C)C)N(C)C(CCCCCN2C(C=CC2=O)=O)=O)=O)C(C)C)=O)[C@H](CC)C)=O)C)=O)CC3=CC=CC=C3)=O)C(N[C@@H](CCCNC(N)=O)C(NC4=CC=C(CO)C=C4)=O)=O)C
|
|||||
| InChI |
InChI=1S/C67H103N11O14/c1-14-43(8)59(76(11)66(89)57(41(4)5)74-65(88)58(42(6)7)75(10)52(80)27-19-16-20-35-78-53(81)32-33-54(78)82)51(91-12)38-55(83)77-36-22-26-50(77)60(92-13)44(9)61(84)72-49(37-45-23-17-15-18-24-45)63(86)73-56(40(2)3)64(87)71-48(25-21-34-69-67(68)90)62(85)70-47-30-28-46(39-79)29-31-47/h15,17-18,23-24,28-33,40-44,48-51,56-60,79H,14,16,19-22,25-27,34-39H2,1-13H3,(H,70,85)(H,71,87)(H,72,84)(H,73,86)(H,74,88)(H3,68,69,90)/t43-,44+,48-,49-,50-,51+,56-,57-,58-,59-,60+/m0/s1
|
|||||
| InChIKey |
ORGBMZJZFMLDBQ-DNIGJBFUSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1286.624
|
Polar area
|
337.62
|
||
|
Complexity
|
2715.53964
|
xlogp Value
|
3.9485
|
|||
|
Heavy Count
|
92
|
Rot Bonds
|
38
|
|||
|
Hbond acc
|
14
|
Hbond Donor
|
8
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
YC1667 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
5.623 ng/mL
|
Positive PSMA expression (PSMA+++/++) | ||
| Method Description |
ADCs (10x the final top concentration) was tested in C4-2B cells for 3 days.
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP cells | CVCL_0395 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
11.16 ng/mL
|
Positive PSMA expression (PSMA+++/++) | ||
| Method Description |
ADCs (10x the final top concentration) was tested in LNCap cells for 3 days.
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP cells | CVCL_0395 | ||